Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multicenter phase II trial of mFOLFOX6 with cetuximab as active chemotherapy regimen for liver metastases inappropriate for curative resection in EGFR positive and KRAS wild type colorectal cancer

ABSTRACT: Interventions: Chemotherapy with modified FOLFOX6 plus cetuximab. Treatment repeats every 14 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Liver resection (if possible, 6 weeks after modified FOLFOX6 plus cetuximab) Primary outcome(s): R0 resection rate (Curative resection rate) Study Design: Single arm Non-randomized

DISEASE(S): Egfr Positive And Kras Wild Type Colorectal Cancer With Liver Metastases Inappropriate For Curative Resection

PROVIDER: 2620128 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Liver resection after chemotherapy for liver only metastasis from colorectal cancer

Project description:Interventions: Chemotherapy with modified FOLFOX6 plus BV(bevacizumab). Treatment repeats every 14 days for up to 6 courses (5 courses for BV) in the absence of disease progression or unacceptable toxicity. Liver resection (if possible, 4 to 8 weeks after modified FOLFOX6 plus BV) Primary outcome(s): Curative resection rate (R0 resection rate) [in all subjects] Study Design: Single arm Non-randomized

| 2617582 | ecrin-mdr-crc

Conversion therapy of Cetuximab plus FOLFIRI followed by Bevacizumab plus mFOLFOX6 in patients with liver metastatic colorectal cancer

Project description:Interventions: Chemotherapy with Cetuximab plus FOLFIRI followed by Bevacizumab plus mFOLFOX6. Treatment repeats every 14 days for up to 12 courses (6 courses for Cetuximab plus FOLFIRI and 6 courses for Bevacizumab plus mFOLFOX6) . Liver resection (if possible) Primary outcome(s): Liver resection rate after chemotherapy with Bevacizumab plus mFOLFOX6(R0/R1) Study Design: Single arm Non-randomized

| 2620139 | ecrin-mdr-crc

Prediction of response to FOLFOX

Project description:The patients who underwent surgery for primary lesions were examined. All patients had metastatic or recurrent CRC and received modified FOLFOX6. Responders and nonresponders were determined based on the best observed response at the end of the first-line treatment, mFOLFOX6. Gene-expression profiles of primary CRC were determined using Human Genome GeneChip arrays U133. Colorectal cancer patients who had undergone surgical resection of colorectal cancer were studied. To identify molecular signatures to predict response to mFOLFOX6 regimen, gene expression profiles were compared between Reponder and Non-responder. Some patients are overlapped with Bevacizumab therapy.

2013-01-03 | E-GEOD-19860 | biostudies-arrayexpress

Randomized study of hepatectomy+mFOLFOX6 vs. hepatectomy alone for liver metastasis of colorectal cancer (JCOG0603)

Project description:Interventions: A: Live resection B: At 56 to 84 days after hepatectomy, patients receive 2-hour infusion of oxaliplatin IV and l-leucovorin on day 1 followed by fluorouracil (5-FU) bolus and 46-hour infusion on day 1. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. Primary outcome(s): Treatment compliance at 9 courses after beginning mFOLFOX6 (phaseII) Disease-free survival (phaseIII) Study Design: Parallel Randomized

| 2616158 | ecrin-mdr-crc

Human colon cancer cell lines: NT(untreated) vs EGF, Cetuximab and Gefitinib treatments

Project description:Gene Expression Profiling of HT-29 and Caco-2 colon cancer cell lines untreated compared with EGF, Cetuximab, Gefitinib,EGF plus Cetuximab and EGF plus gefitinib treatments. Keywords: Gene Expression Profiling

2007-09-12 | GSE8967 | GEO

A multicenter randomized phase II/III trial of preoperative versus postoperative chemotherapy with XELOX plus bevacizumab in patients with resectable colorectal liver metastasis.

Project description:Interventions: A: Within 56 days after surgery, patients receive infusional oxaliplatin and oral capecitabine. Patients receive infusional bevacizumab as from second course. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. B: Patients receive infusional oxaliplatin, bevacizumab and oral capecitabine. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients do not receive bevacizumab at last course. Within 56 days after chemotherapy, patients receive surgery. Primary outcome(s): Treatment compliance (phase II) Progression-free survival (phase III) Study Design: Parallel Randomized

| 2619239 | ecrin-mdr-crc

JCOG0603: Randomized study of hepatectomy+mFOLFOX6 vs. hepatectomy alone for liver metastasis of colorectal cancer

| 2614114 | ecrin-mdr-crc

Prediction of response to FOLFOX

2013-01-03 | GSE19860 | GEO

A phase I/II study of hepatic arterial 5-flurouracil (5FU) combined with intravenous irinotecan hydrochloride (CPT-11) for metastatic colorectal cancer isolated in the liver. (JCOG 0208-DI)

Project description:Interventions: Patients undergo implantation of hepatic arterial catheter and port system percutaneously, and then, receive hepatic arterial administration of 5-fluorouracil at day 1,8, and 15 followed by intravenous administration of irinotecan hydrochloride at day 1 and 15. Treatment repeats every 4 weeks for 5 courses in the absence of disease progression or unacceptable toxicity. Primary outcome(s): Adverse events Study Design: Single arm Non-randomized

| 2609482 | ecrin-mdr-crc

Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer

Project description:Colorectal cancer (CRC) patients suffer from the second highest mortality among all cancer entities. In half of all CRC patients, colorectal cancer liver metastases (CRLM) can be observed. Metastatic colorectal cancer is associated with poor overall survival and limited treatment options. Even after successful surgical resection of the primary tumor, metachronous liver metastases occur in one out of eight cases. The only available curative intended treatment is hepatic resection, but metachronous CRLM frequently recur after approximately one year. In this study, we performed a proteome analysis of three recurrent liver metastases of a single CRC patient by mass spectrometry. Despite surgical resection of the primary CRC and adjuvant chemotherapy plus cetuximab treatment, the patient developed three metachronous CRLM which occurred consecutively after 9, 21 and 31 months. We identified a set of 1,132 proteins expressed in the three metachronous CRLM, of which 481 were differentially regulated, including 81 proteins that were associated with the extracellular matrix (ECM). 56 ECM associated proteins were identified as upregulated in the third metastasis, 26 (46%) of which were previously described as negative prognostic markers in CRC, including tenascin C, nidogen 1, fibulin1 and vinculin. These data may reflect an ascending trend of malignancy from the first to the third metachronous colorectal cancer liver metastasis. Additionally, the results indicate different ECM phenotypes for recurrent metachronous metastasis, associated with different grades of malignancy and highlights the importance of individual analysis of molecular features in different, consecutive metastatic events in a single patient.

2021-09-09 | PXD020109 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data